Skip to main contentSkip to navigation Close dialogue1/2 Next image Previous image Toggle captionSkip to navigation GSK acquired the Mo-Rez treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharm. Photograph: Brian Jackson/Alamy View image in fullscreen GSK acquired the Mo-Rez treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharm. Photograph: Brian Jackson/Alamy GSK reports promising early results in ovarian and womb cancer drug trialMo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug GSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.Based in London, GSK has recently gained plaudits for its work on tackling superbugs, becoming one of just three big pharma companies globally that continue to invest in anti-microbial research.However, commercially GSK has been eclipsed in recent years by its bigger British rival AstraZeneca, which last year outstripped GSK’s near-£33bn turnover by more than £10bn and whose market value is more than twice as high.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in…
Published: April 12, 2026 3:12 pm
Source: The Guardian — Read original